KYNB KYNTRA BIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, KYNTRA BIO INC reported revenue of −$1.47M (down 209.3% from a year earlier), net income of $12.0M and diluted EPS of $2.96; over the last four quarters revenue was $4.62M and net income $183M; for the fiscal year ended December 2025 revenue was $6.44M, down 78.3% on the year before.
KYNB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $6.44M, gross profit n/a, operating income −$45.9M, net income $183M (margin 2848.6%), EPS $45.37
- Fiscal year ended Dec 2024: revenue $29.6M, gross profit n/a, operating income −$150M, net income −$47.6M (margin -160.6%), EPS −$11.89
- Fiscal year ended Dec 2023: revenue $46.8M, gross profit n/a, operating income −$323M, net income −$284M (margin -607.3%), EPS −$2.92
- Fiscal year ended Dec 2022: revenue $141M, gross profit n/a, operating income −$301M, net income −$294M (margin -208.7%), EPS −$3.14
- Fiscal year ended Dec 2021: revenue $235M, gross profit n/a, operating income −$289M, net income −$290M (margin -123.3%), EPS −$3.14
KYNB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue −$1.47M (down 209.3% year over year), net income $12.0M, EPS $2.96
- Quarter ended Mar 31, 2026: revenue $3.74M (up 36.5% year over year), net income −$15.2M, EPS −$3.76
- Quarter ended Dec 31, 2025 (from the annual report): revenue $1.28M (down 59.3% year over year), net income −$14.2M, EPS −$3.51
- Quarter ended Sep 30, 2025: revenue $1.08M (up 774.8% year over year), net income $201M, EPS $49.61
- Quarter ended Jun 30, 2025: revenue $1.35M (up 35.1% year over year), net income −$7.60M, EPS −$1.88
- Quarter ended Mar 31, 2025: revenue $2.74M (down 89.2% year over year), net income $4.64M, EPS $1.15
- Quarter ended Dec 31, 2024 (from the annual report): revenue $3.14M (up 104.2% year over year), net income $18.0M, EPS −$3.42
- Quarter ended Sep 30, 2024: revenue $123K (down 99.7% year over year), net income −$17.1M, EPS −$4.25
- Quarter ended Jun 30, 2024: revenue $998K (down 97.7% year over year), net income −$15.5M, EPS −$3.89
- Quarter ended Mar 31, 2024: revenue $25.4M (down 29.9% year over year), net income −$32.9M, EPS −$0.33
- Quarter ended Dec 31, 2023 (from the annual report): revenue −$73.8M (down 314.8% year over year), net income −$56.2M, EPS −$0.56
- Quarter ended Sep 30, 2023: revenue $40.1M (up 155.1% year over year), net income −$63.6M, EPS −$0.65
- Quarter ended Jun 30, 2023: revenue $44.3M (up 48.7% year over year), net income −$87.7M, EPS −$0.90
- Quarter ended Mar 31, 2023: revenue $36.2M (down 40.6% year over year), net income −$76.7M, EPS −$0.81
- Quarter ended Dec 31, 2022 (from the annual report): revenue $34.4M (up 107.7% year over year), net income −$66.2M, EPS −$0.70
- Quarter ended Sep 30, 2022: revenue $15.7M (down 89.9% year over year), net income −$91.7M, EPS −$0.98
- Quarter ended Jun 30, 2022: revenue $29.8M (up 22.3% year over year), net income −$72.6M, EPS −$0.78
- Quarter ended Mar 31, 2022: revenue $60.8M (up 58.3% year over year), net income −$63.2M, EPS −$0.68
- Quarter ended Dec 31, 2021 (from the annual report): revenue $16.5M, net income −$134M, EPS −$1.45
- Quarter ended Sep 30, 2021: revenue $156M, net income $49.8M, EPS $0.54
KYNB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$4.77M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$138M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$315M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$146M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$82.2M, share buybacks n/a
KYNB balance sheet
- Jun 30, 2026: cash $50.6M, total assets $101M, total liabilities $109M, shareholders' equity −$30.1M
- Mar 31, 2026: cash $37.0M, total assets $110M, total liabilities $119M, shareholders' equity −$43.8M
- Dec 31, 2025: cash $47.9M, total assets $120M, total liabilities $115M, shareholders' equity −$30.0M
- Sep 30, 2025: cash $118M, total assets $137M, total liabilities $120M, shareholders' equity −$17.0M
- Jun 30, 2025: cash $23.4M, total assets $178M, total liabilities $359M, shareholders' equity −$223M
- Mar 31, 2025: cash $33.6M, total assets $165M, total liabilities $340M, shareholders' equity −$217M
- Dec 31, 2024: cash $50.5M, total assets $215M, total liabilities $398M, shareholders' equity −$226M
- Sep 30, 2024: cash $131M, total assets $264M, total liabilities $466M, shareholders' equity −$244M
What is KYNB's revenue?
KYNTRA BIO INC reported $4.62M of revenue over its last four quarters, through June 30, 2026.
Is KYNB profitable?
Yes. KYNTRA BIO INC earned $183M over the last four quarters.
What is KYNB's EPS?
Diluted earnings per share over the last four quarters were $45.30; $2.96 in the latest quarter.